Department of Digestive and Oncologic Surgery, AP-HP, Hôpital Ambroise Paré, Université Versailles Saint Quentin en Yvelines, Versailles, France.
J Surg Oncol. 2010 Dec 15;102(8):932-6. doi: 10.1002/jso.21657.
Neoadjuvant chemotherapy is increasingly used to improve outcome in patients with colorectal liver metastases (CLM). In patients with unresectable CLM, recent clinical trials evaluate the ability of chemotherapy to increase the resectability rate. In patients with resectable CLM, the objective is to decrease the risk of recurrence after hepatectomy that still remains elevated despite the improvement of the surgical technique. A multidisciplinary approach of patients with CLM is desirable whatever the initial status of resectability.
新辅助化疗越来越多地用于改善结直肠癌肝转移（CLM）患者的预后。对于不可切除的 CLM 患者，最近的临床试验评估了化疗增加可切除率的能力。对于可切除的 CLM 患者，其目的是降低肝切除术后复发的风险，尽管手术技术有所改善，但复发风险仍然很高。无论初始可切除性如何，对 CLM 患者进行多学科治疗都是可取的。
